November 2024 Br J Cardiol 2024;31(4) doi:10.5837/bjc.2024.046 Online First
Mohamed ElRefai, Mohamed Abouelasaad, Alice Zheng, Chitsa Seyani, Amy Greenwood, Hari Johal, Jake Hudson, Claire O’Dowling, Chris Young, Paul Haydock
Introduction Dapagliflozin is a well-established treatment for type 2 diabetes mellitus (T2DM) that belongs to a class of medications called sodium-glucose cotransporter type 2 inhibitors (SGLT2i). It exerts its hypoglycaemic effect through reversibly inhibiting SGLT2 in the renal proximal convoluted tubule to reduce glucose re-absorption and increase urinary glucose excretion. Several well-designed randomised-controlled trials were conducted to assess the cardiovascular safety and efficacy of dapagliflozin, when administered at a dose of 10 mg once daily, in reducing cardiovascular events and related hospitalisations associated with heart f
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits